Evidence map›Paper›PMID 29235050›Full record

ArticleJournal of endocrinological investigation2018

Copeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study.

S Canivell, M Mohaupt, D Ackermann, M Pruijm, I Guessous, G Ehret, G Escher, A Pechère-Bertschi, B Vogt, O Devuyst and 4 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

S CanivellInstitute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland. scanivell@gmail.com.ORCID http://orcid.org/0000-0002-0280-5035
M MohauptUniversity Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
D AckermannUniversity Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
M PruijmService of Nephrology and Hypertension, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
I GuessousDepartment of Community Medicine, Primary Care and Emergency Medicine, University Hospital of Geneva, Geneva, Switzerland.
G EhretCardiology Service, Department of Specialties of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland.
G EscherUniversity Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
A Pechère-BertschiUnit of Hypertension, Departments of Specialties of Medicine and Community Medicine and Primary Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.
B VogtUniversity Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
O DevuystInstitute of Physiology, University of Zurich, Zurich, Switzerland.
M BurnierNephrology Service, University Hospital of Lausanne, Lausanne, Switzerland.
P-Y MartinNephrology Service, Department of Specialties of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland.
B PonteNephrology Service, Department of Specialties of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland.
M BochudInstitute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland.
University of Bern · CHUniversity Hospital of Geneva · CHInstitute of Social and Preventive Medicine · CHUniversity Hospital of Lausanne · CHUniversity of Zurich · CH

Funding

European Foundation for the Study of Diabetes Albert Renold FellowshipHôpitaux Universitaires de Genève Tremplin fundingSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung FN 33CM30-124087
6 · The paper itself

Abstract

purposeArginine vasopressin (AVP) may be involved in metabolic syndrome (MetS) by altering liver glycogenolysis, insulin and glucagon secretion, and pituitary ACTH release. Moreover, AVP stimulates the expression of 11β-hydroxysteroid-dehydrogenase-type 2 (11β-HSD2) in mineralocorticosteroid cells. We explored whether apparent 11β-HSD2 activity, estimated using urinary cortisol-to-cortisone ratio, modulates the association between plasma copeptin, as AVP surrogate, and insulin resistance/MetS in the general adult population.

methodsThis was a multicentric, family-based, cross-sectional sample of 1089 subjects, aged 18-90 years, 47% men, 13.4% MetS, in Switzerland. Mixed multivariable linear and logistic regression models were built to investigate the association of insulin resistance (HOMA-IR)/fasting glucose and MetS/Type 2 Diabetes with copeptin, while considering potential confounders or effect modifiers into account. Stratified results by age and 11β-HSD2 activity were presented as appropriate.

resultsPlasma copeptin was higher in men [median 5.2, IQR (3.7-7.8) pmol/L] than in women [median 3.0, IQR (2.2-4.3) pmol/L], P < 0.0001. HOMA-IR was positively associated with copeptin after full adjustment if 11β-HSD2 activity was high [β (95% CI) = 0.32 (0.17-0.46), P < 0.001] or if age was high [β (95% CI) = 0.34 (0.20-0.48), P < 0.001], but not if either 11β-HSD2 activity or age was low. There was a positive association of type 2 diabetes with copeptin [OR (95% CI) = 2.07 (1.10-3.89), P = 0.024), but not for MetS (OR (95% CI) = 1.12 (0.74-1.69), P = 0.605), after full adjustment.

conclusionsOur data suggest that age and apparent 11β-HSD2 activity modulate the association of copeptin with insulin resistance at the population level but not MeTS or diabetes. Further research is needed to corroborate these results and to understand the mechanisms underlying these findings.

Indexed as

11-beta-Hydroxysteroid Dehydrogenase Type 2AdultAgedAged, 80 and overAge FactorsAgingCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleGlycopeptidesHumansInsulin ResistanceMaleMetabolic SyndromeMiddle AgedYoung Adult11-beta-Hydroxysteroid Dehydrogenase Type 2copeptinsGlycopeptides11-β hydroxysteroid dehydrogenase type 2 enzymeAgingCopeptinInsulin resistanceInteraction

Identifiers

PMID29235050
OpenAlexW2773913606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.